Home > Insider Trading > Filing (0000899243-20-011186)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1243847	B John Green	C/O Dicerna Pharmaceuticals, Inc. 33 Hayden Avenue Lexington MA 02421	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-04-20	25,624	$5.45	45,045	No	4	M	Direct
Common Stock	Disposition	2020-04-20	25,624	$22.95	19,421	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-04-20	25,624	$0.00	25,624	$5.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
186,375		2026-04-14	No	4	M	Direct

Footnotes

Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
The reporting person sold an aggregate of 25,624 shares of common stock on April 20, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 4.01% of 638,583 shares of common stock, which is the number of shares of common stock owned by the reporting person prior to the Shares Sold transactions reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the reporting person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2019.
As of the transaction date, the option was fully vested. The option vested 25% after the first year anniversary of the vesting start date of April 14, 2016 and the remaining 75% vested in 36 substantially equal monthly installments thereafter, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.